Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Nakasone, Hideki  [Clear All Filters]
2024
Konuma T, Harada K, Shinohara A, Uchida N, Shingai N, Ito A, Ozawa Y, Tanaka M, Sawa M, Onizuka M, et al. Association of individual comorbidities with outcomes in allogeneic hematopoietic cell transplantation from unrelated adult donors versus unrelated cord blood: A study on behalf of the Donor/Source and Transplant Complications Working Groups of the Japane. Am J Hematol. 2024.
2023
Okada Y, Kimura F, Kurita N, Takahashi H, Shimazu Y, Mizuno S, Uchida N, Kataoka K, Hiramoto N, Ota S, et al. Adverse impact of delay of platelet recovery after autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma and multiple myeloma. Cytotherapy. 2023.
Yanagisawa R, Koyama H, Yakushijin K, Uchida N, Jinguji A, Takeda W, Nishida T, Tanaka M, Eto T, Ohigashi H, et al. Analysis of risk factors for fatal renal complications after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2023.
Nakamura Y, Kawamura S, Matsumi S, Matsumoto K, Tanaka S, Ishikawa T, Matsuoka A, Meno T, Kawamura M, Takeshita J, et al. [Anti-MDA5 antibody-positive rapidly progressive interstitial lung disease after allogeneic hematopoietic cell transplantation successfully treated with triple immunosuppressive therapy]. Rinsho Ketsueki. 2023;64(4):250-254.
Yoshino N, Kimura S-I, Matsuoka A, Meno T, Ishikawa T, Nakamura Y, Kawamura M, Takeshita J, Kawamura S, Misaki Y, et al. Clinical features of febrile neutropenia and bloodstream infection in autologous hematopoietic cell transplantation: Comparison to those in intensive chemotherapy for acute myeloid leukemia. J Infect Chemother. 2023.
Konuma T, Yamasaki S, Ishiyama K, Mizuno S, Hayashi H, Uchida N, Shimabukuro M, Tanaka M, Kuriyama T, Onizuka M, et al. Comparison of allogeneic transplant outcomes between matched sibling donors and alternative donors in patients over 50 years of age with acute myeloid leukemia: 8/8 allele-matched unrelated donors and unrelated cord blood provide better leukemia-free surv. Transplant Cell Ther. 2023.
Kusuda M, Nakasone H, Yoshimura K, Okada Y, Tamaki M, Matsuoka A, Ishikawa T, Meno T, Nakamura Y, Kawamura M, et al. Gene expression and TCR amino acid sequences selected by HLA-A02:01-restricted CTLs specific to HTLV-1 in ATL patients. Br J Haematol. 2023.
Tamaki M, Akahoshi Y, Ashizawa M, Misaki Y, Koi S, Kim S-W, Ozawa Y, Fujiwara S-I, Kako S, Matsuoka K-I, et al. Impact of anti-thymocyte globulin on survival outcomes in female-to-male allogeneic hematopoietic stem cell transplantation. Sci Rep. 2023;13(1):7166.
Hayashi H, Iwasaki M, Nakasone H, Tanoshima R, Shimabukuro M, Takeda W, Nishida T, Kako S, Fujiwara S-I, Katayama Y, et al. Impact of stem cell selection between bone marrow and peripheral blood stem cells for unrelated hematopoietic stem cell transplantation for hematologic malignancies: on behalf of the Donor/Source Working Group of the Japanese Society for Transplantation a. Cytotherapy. 2023.
Takenaka K, Fuji S, Matsukawa T, Uchida N, Kobayashi T, Tanaka M, Ara T, Ikegame K, Ozawa Y, Kanda Y, et al. Outcomes of allogeneic hematopoietic cell transplantation under letermovir prophylaxis for cytomegalovirus infection. Ann Hematol. 2023.
Matsumi S, Kimura S-I, Nakamura Y, Kawamura M, Takeshita J, Kawamura S, Yoshino N, Misaki Y, Yoshimura K, Gomyo A, et al. Substitution of calcineurin inhibitors with corticosteroids after allogeneic hematopoietic cell transplantation. Int J Hematol. 2023.
2022
Tamaki M, Kameda K, Kimura S-I, Harada N, Uchida N, Doki N, Tanaka M, Ikegame K, Sawa M, Katayama Y, et al. Deletion of Y-chromosome before allogeneic hematopoietic stem cell transplantation in male recipients with female donors. Blood Adv. 2022.
Okada Y, Nakasone H, Konuma T, Uchida N, Tanaka M, Sugio Y, Aotsuka N, Nishijima A, Katsuoka Y, Ara T, et al. Ideal body weight is useful for predicting neutrophil engraftment and platelet recovery for overweight and obese recipients in single-unit cord blood transplantation. Transplant Cell Ther. 2022.
Kimura S-I, Kameda K, Harada K, Saburi M, Okinaka K, Shinohara A, Uchida N, Nishijima A, Ozawa Y, Tanaka M, et al. Risk and predictive factors for candidemia after allogeneic hematopoietic cell transplantation: JSTCT Transplant Complications Working Group. Transplant Cell Ther. 2022.
Kawamura S, Tamaki M, Nakamura Y, Kawamura M, Takeshita J, Yoshino N, Misaki Y, Yoshimura K, Matsumi S, Gomyo A, et al. Successful treatment of the TEMPI syndrome with pomalidomide plus dexamethasone followed by autologous stem cell transplantation. Acta Haematol. 2022.
2021
Takeshita J, Kimura S-I, Nakasone H, Kawamura S, Nakamura Y, Kawamura M, Yoshino N, Misaki Y, Yoshimura K, Matsumi S, et al. Association between the kinetics of cytomegalovirus reactivation in terms of the area under the curve of cytomegalovirus antigenemia and non-relapse mortality after allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis. 2021.
Kawamura S, Nakasone H, Takeshita J, Kimura S-I, Nakamura Y, Kawamura M, Misaki NYoshinoYuk, Yoshimura K, Matsumi S, Gomyo A, et al. Prediction of CMV reactivation by recipient CMV-IgG titer before allo-HCT. Transplant Cell Ther. 2021.
2020
Kimura S-I, Takeshita J, Kawamura M, Kawamura S, Yoshino N, Misaki Y, Yoshimura K, Matsumi S, Gomyo A, Akahoshi Y, et al. Association between the kinetics of cytomegalovirus reactivation evaluated in terms of the area under the curve of cytomegalovirus antigenemia and invasive mold infection during the post-engraftment phase after allogeneic hematopoietic stem cell transplan. Transpl Infect Dis. 2020:e13387.
Harada K, Fuji S, Seo S, Uchida N, Kawakita T, Yano S, Ozawa Y, Yoshioka S, Onishi Y, Noguchi Y, et al. Comparison of immunosuppressant regimens in salvage cord blood transplantation for graft failure after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2020.
Akahoshi Y, Nakasone H, Kawamura K, Kusuda M, Kawamura S, Takeshita J, Yoshino N, Misaki Y, Yoshimura K, Gomyo A, et al. Detection of T315I using digital PCR in allogeneic transplant recipients with Ph-positive ALL in the dasatinib era. Exp Hematol. 2020.
Akahoshi Y, Kimura S-I, Inamoto Y, Seo S, Muranushi H, Shimizu H, Ozawa Y, Tanaka M, Uchida N, Kanda Y, et al. Effect of cytomegalovirus reactivation with or without acute graft-versus-host disease on the risk of nonrelapse mortality. Clin Infect Dis. 2020.
Yokoyama H, Takenaka K, Nishida T, Seo S, Shinohara A, Uchida N, Tanaka M, Takahashi S, Onizuka M, Kozai Y, et al. Favorable effect of cytomegalovirus reactivation on outcomes in cord blood transplantation and its differences among disease risk or types. Biol Blood Marrow Transplant. 2020.
Kimura S-I, Nakamura Y, Kawamura M, Takeshita J, Kawamura S, Yoshino N, Misaki Y, Yoshimura K, Matsumi S, Gomyo A, et al. Impact of neutropenia evaluated in terms of the D-index on invasive fungal disease while on empiric or preemptive antifungal treatment strategy in the early phase after allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis. 2020:e13409.
Takenaka K, Onishi Y, Mori T, Hirakawa T, Tada Y, Uchida N, Kobayashi T, Kanda Y, Ozawa Y, Ota S, et al. Negative Impact of Cytomegalovirus Reactivation on Survival in Adult Patients with Aplastic Anemia After an Allogeneic Hematopoietic Stem Cell Transplantation: A Report from Transplantation-Related Complication and Adult Aplastic Anemia Working Groups of . Biol Blood Marrow Transplant. 2020.
2019
Akahoshi Y, Nakasone H, Kawamura K, Kusuda M, Kawamura S, Takeshita J, Yoshino N, Misaki Y, Yoshimura K, Gomyo A, et al. Increased Mac-2 binding protein glycan isomer in patients at risk for late nonrelapse mortality after HSCT. Blood Adv. 2019;3(21):3287-3296.

Pages